Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Ses... ( Atherotech to add new apoA1 measu...)

Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008

Date:11/6/2008

Atherotech to add new apoA1 measurement and apoB:apoA1 ratio to its comprehensive cholesterol test, further identifying patients at risk of

heart disease

BIRMINGHAM, Ala., Nov. 6 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP(R) Cholesterol Test in booth No. 2918 at the American Heart Association Scientific Sessions 2008. The annual meeting takes place Nov. 8-12 at the Ernest N. Morial Convention Center in New Orleans.

Atherotech representatives will be available to discuss the VAP Cholesterol Test during regular exhibit hours on October 9, 10 and 11 in booth No. 2918, and the VAP Test will be provided via blood draw to qualified attendees. Test results will be returned via mail after the conference.

The VAP (vertical auto profile) Test is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters - LDL, non-HDL and apoB - considered necessary by the 2008 expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology.

"Detailed risk profiling through advanced lipid testing is changing the way we evaluate and manage heart disease risk," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The VAP Test is affordable, widely covered by insurance and will play an increasingly important role in heart attack and stroke prevention."

The VAP Test reports all 15 lipoprotein measurements with a single test, and unlike other lipid profiles, it directly measures LDL and HDL and includes Lp(a) and apoB as part of its standard test. Atherotech has announced plans to add apolipoprotein A-1 (apoA1) to its reporting in early 2009. ApoA1 is the main component of protective HDL cholesterol and studies have shown that the apoB:apoA1 ratio may correlate better with increased risk of coronary artery disease (CAD) than total cholesterol and LDL:HDL rat
'/>"/>

1

GOOD

Page: 1 2
Related biology technology :

1. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
2. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
3. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
4. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
5. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
6. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
9. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
10. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting
11. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007

Post Your Comments:

Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Ses...( Atherotech to add new apoA1 measu...)